Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: Long-term efficacy results: A Hellenic Cooperative Oncology Group (HeCOG) study

Annals of Oncology

Volumn 16, Issue 7, 2005, Pages 1116-1122

  Aravantinos, G ^a,k   Fountzilas, G ^b   Kosmidis, P ^c   Dimopoulos, M A ^d   Stathopoulos, G P ^e   Pavlidis, N ^f   Bafaloukos, D ^g   Papadimitriou, C ^d   Karpathios, S ^d   Georgoulias, V ⁱ   Papakostas, P ^h   Kalofonos, H P ^j   Grimani, E ^a   Skarlos, D V ^e  

^a AGII ANARGIRI CANCER HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c HYGEIA HOSPITAL   (Greece)

^d ALEXANDRA HOSPITAL   (Greece)

^e HENRY DUNANT HOSPITAL   (Greece)

^f UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^g METROPOLITAN HOSPITAL   (Greece)

^h IASO GENERAL HOSPITAL   (Greece)

ⁱ UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^j University Hospital of Rio   (Greece)

^k Helenic Cooperative Oncology Group   (Greece)

more..

Author keywords

Alternating cisplatin with carboplatin; Chemotherapy; Initial treatment; Ovarian cancer

Indexed keywords

CARBOPLATIN; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIMETINDENE; GRANULOCYTE COLONY STIMULATING FACTOR; ONDANSETRON; PACLITAXEL; PROMETHAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER PATIENT; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PAIN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDARDIZATION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; OVARY TUMOR; PATIENT COMPLIANCE; PROSPECTIVE STUDY; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 25444463805     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi223     Document Type: Article

References (23)

1. McGuire WP, Hoskins WJ, Brady MR et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
2. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 2000; 92: 699.
3. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2003; 21: 3194-3200.
4. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084-3092.
5. Du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
6. Gore ME, Fryatt I, Wiltshow E et al. Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 1989; 60: 767-769.
7. Lund B, Hansen M, Hansen OP, Hansen H. High dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 1989; 7: 1469-1473.
8. Piccart MJ, Nogaret JM, Marcelis L et al. Cisplatin combined with carboplatin: A new way of intensification of platinum dose in the treatment of advanced ovarian cancer. J Natl Cancer Inst 1990; 82: 703-707.
9. Skarlos D, Aravantinos G, Kosmidis P et al. Paclitaxel with carboplatin vs paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: Preliminary results of a Hellenic Cooperative Oncology Group study. Semin Oncol 1997; 24 (Suppl 15): 57-61.
10. Aravantinos G, Fountzilas G, Kosmidis P et al. Combination paclitaxel plus carboplatin versus paclitaxel with alternating carboplatin and cisplatin as first line treatment for advanced ovarian cancer (AOC). Ann Oncol 1998; 9 (Suppl 4): 66 (Abst 316).
11. Aravantinos G, Fountzilas G, Kosmidis P et al. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer (AOC): A Hellenic Co-Operative Oncology Group Study. Proc Am Soc Clin Oncol 1999; 18: (Abstr 367a).
12. Aravantinos G, Fountzilas G, Kosmidis P et al. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer (AOC). Long-term efficacy results. Eur J Cancer 2003; 1 (Suppl 5): S15.
13. Calvert AH, Newell R, Gumbrell LA et al. Carboplatin dosage:pRospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-1756.
14. Jelliffe RW. Creatinine clearance: Bedside estimate. Ann Intern Med 1973; 79: 604-605.
15. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
16. Agresti A. Categorical Data Analysis. New York, NY: John Wiley & Sons 1990.
17. Lentner C. Geigy Scientific Tables ('Exact Confidence Limits for p'). Switzerland: Ciba-Geigy 1982; 89-102.
18. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1985; 53: 229-232.
19. Cox D. Regression models and life tables (with discussion). J Royal Stat Soc B 1972; 34: 187-220.
20. Ozols RF. Future directions in the chemotherapy of Ovarian Cancer. Semin Oncol 1997; 24 (Suppl 15): 86-90.
21. du Bois A, Neijt JP, Thigpen Jt. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer-a new standard of care? Ann Oncol 1999; 10 (Suppl 1): S35-S41.
22. The ICON Group. Paclitaxel plus carboplatin versus standard chemotherapy with ither single-agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: ICON-3 randomised trial. Lancet 2002; 360: 505-515.
23. Skarlos DV, Aravantinos G, Kosmidis P et al. Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: A Hellenic Cooperative Oncology Group Study. Eur J Cancer 1996; 3: 421-428.